We primarily invest in early-stage companies, and on occasion, we are flexible to invest in opportunities at adjacent stages when it makes sense.
We are generalist investors. As a general rule, life sciences and crypto are outside of our investment scope.
Europe is our usual playing field. We may opportunistically invest in the U.S. and LatAm.
We are flexible and adapt to the needs of each round. While we often co-invest, we also lead or co-lead when it adds value.
We invest early-stage, from pre-seed to Series B. Our initial checks go up to €3M, and we usually take single-digit ownership stakes.
We follow on selectively and support companies to achieve their milestones and long-term success.
We support our portfolio along the way - typically up to series B. We take a dynamic approach that changes follow-on allocation over time. As a general rule, we treat follow-on investments as initial investments, requesting at least a 10x potential return from them.
We are strong believers in capital efficiency, both in bull and bear markets. We look thoroughly at unit economics and bet on models with realistic paths to profitability in the medium and long runs. Valuations are important for us, even at very early stages, and we do not hesitate to walk away from a deal if the numbers don't add up
We typically don’t take formal board or observer roles, nor are we on founders’ backs every day. Instead, we position ourselves as a trusted partner, available whenever our companies need us. We leverage our community—including corporate partners and industry experts—to support their growth, making strategic introductions, providing guidance, and collaborating closely to tackle challenges and seize opportunities. Our goal is to work hand-in-hand with founders, adding meaningful value and helping them scale effectively.
